With the widespread routine use of NAC for TNBC and HER2-positive BC patients 1 2, second-line trials in the post neoadjuvant setting for high risk patients are increasing testing the addition of chemotherapy, PARP inhibitors [36], immunotherapy [37], cyclin-dependent kinase inhibitors [38], or vaccines [39]. This evidence concerns the gene ERBB2 and breast cancer.